Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Thanks to computer numerical control (CNC) fabrication technologies, the method may also be applied to design-laminated timber gridshells. Credit: ©2025 Masaaki Miki and Toby Mitchell CC-BY-ND A new ...
Albany International Initiates Review of Strategic Alternatives for Structures Assembly Business; Announces Loss Reserve Adjustment for CH-53K Program; Schedules Earnings Release Date Third-Quarter ...
VALDOSTA — With a focus on developing forward-thinking, future-ready graduates with the skills, knowledge, and agility needed to succeed in a rapidly evolving global landscape, Valdosta State ...
Chip programming solutions provider Data I/O was recently targeted in a ransomware attack that has caused significant disruption to the company’s operations. Data I/O offers electronic device ...
The credit card processing industry is undergoing a major change since Visa announced the Commercial Enhanced Data Program (CEDP), which went live in the U.S. in April. This new program replaces the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback